Context
• Nivolumab (Opdivo) is the original cancer immunotherapy drug developed by Bristol Myers Squibb.
• Immunotherapy treats cancer by activating the body’s immune system instead of directly killing cancer cells like chemotherapy.
• Delhi High Court ruling allows Indian companies to make biosimilar versions of Nivolumab.
• This is expected to significantly reduce costs and improve access.
